These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23514013)

  • 1. Myelofibrosis: an update on current pharmacotherapy and future directions.
    Cervantes F; Martinez-Trillos A
    Expert Opin Pharmacother; 2013 May; 14(7):873-84. PubMed ID: 23514013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How I treat myelofibrosis.
    Cervantes F
    Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of myelofibrosis: JAK inhibition and beyond.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I manage anemia related to myelofibrosis and its treatment regimens.
    Verstovsek S
    Ann Hematol; 2023 Apr; 102(4):689-698. PubMed ID: 36786879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for myelofibrosis.
    Atallah E; Verstovsek S
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs for the treatment of myelofibrosis.
    Mesa RA
    Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
    Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
    Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clarifying the use of ruxolitinib in patients with myelofibrosis.
    Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
    Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
    Vaddi K; Sarlis NJ; Gupta V
    Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State-of-the-Art Review on Myelofibrosis Therapies.
    Wang F; Qiu T; Wang H; Yang Q
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic management of myelofibrosis.
    Leung M; Highsmith K; Rexwinkle A
    J Oncol Pharm Pract; 2017 Dec; 23(8):591-601. PubMed ID: 27672139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ruxolitinib for myelofibrosis.
    Santos FP; Verstovsek S
    Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Myelofibrosis: A Moving Target.
    Cerquozzi S; Farhadfar N; Tefferi A
    Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
    Saleh K; Ribrag V
    Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelofibrosis: diagnosis and treatment.
    Barranco-Lampón G; Martínez-Castro R; Arana-Luna L; Álvarez-Vera JL; Rojas-Castillejos F; Peñaloza-Ramírez R; Carballo-Zarate AA; Olarte-Carrillo I; Minamy JI; López-Salazar J; Navarrete JJ; Espinosa-Partida A; Ventura-Enríquez Y; Ruiz-Contreras JI; Aguirre-Reyes OG; Anaya-Cuéllar I; Aguilar-Luévano J; Díaz-Ramírez HF; Herrera-Olivares W; Aguilar-Hidalgo JA; Alcívar-Cedeño LM; Hernández-Caballero Á; Galaz-Cordero LE; Peña-Celaya JA; Báez-Islas PE; Bates-Martín RA; Cano-León AML; Espitia-Ríos ME; Barbosa D; Morales-Adrián J; Pacheco MJ; Delgado-López N; Neme-Yunes Y; Moralws-Hernández AE; Mújica-Martínez A; Pérez-Lizardi AB; Pérez-Gómez KD; Barragán-Ibáñez G; Martínez A; Flores-Ordúñez K; Ramírez-Hoyos P; Rosales-López MLÁ; Acosta-Maldonado BL; Jiménez-Ochoa MA; Garzón-Velásquez KB; Hernández-Ruiz E; McNally-Guillén BM; Saucedo-Montes EE; Aguilar-Andrade C; Vivas-Arteaga CL; Guerra-Alarcón LV; Milán-Salvatierra AI; Campa-Monroy DI; Cota-Rangel X; Estrada-Domínguez P; García-Camacho AS; García-Castillo C; Banda-García LI; Rodríguez-Sánchez V; Meillón-García LA; Urbina-Escalante E; Martínez-Ramírez MA; Loera-Fragoso SJ; Martínez-Coronel J; Zapata-Canto N; Gómez-Cortés SC; Medina-Coral JE; Mójica-Balderas L; Pérez-Zúñiga JM; Pérez FJ; López-Arroyo JL; Zazueta-Pozos JF; Romero-Martínez E; Romero-Rodelo H; Tapia-Enríquez AL; Soriano-Mercedes EJ; Salazar-Ramírez Ó; Vilchis-González SP; Tepepa-Flores F; Alvarado-Ibarra M
    Gac Med Mex; 2022; 158(Supl 1):26-37. PubMed ID: 37734057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman G; Mascarenhas J
    Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
    Morsia E; Gangat N
    Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
    [No Abstract]   [Full Text] [Related]  

  • 20. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.